Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
Clinical trial NCT02890381 · TERMINATED
Trial details
- NCT number
- NCT02890381
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-05
- Primary completion
- 2017-04-24
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.